KIRIN-HOLDINGS
Kirin Holdings Company, Limited (Kirin) will launch as a new business in the Health Science domain (Health Science business) a limited offering of 200 units of Electric Salt Spoon, which enhances the salty and umami taste of low-sodium foods with the power of electricity, on Monday, May 20, 2024 at its official online store (https://electricsalt.shop.kirin.co.jp/). In addition, a limited number of units will be available at Hands Inc. stores beginning in June.
This tableware-type device is equipped with technology that enhances the salty taste perceived when eating low-sodium foods by approximately 1.5 times*2,3. The technology was developed through joint research with the Meiji University Dr. Homei Miyashita Laboratory of the Department of Frontier Media Science, School of Interdisciplinary Mathematical Sciences (Miyashita Laboratory). Through this device, we aim to realize a society in which people can improve their lifestyle in a delicious way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240519949395/en/
Target and current levels of salt intake (g/day) (Graphic: Business Wire)
| 1. |
The 3rd Neurostimulation Interface Research Meeting. March 2023
|
| 2. | KIRIN news release on April 11, 2022 https://www.kirinholdings.com/jp/newsroom/release/2022/0411_01.html |
| 3. | Change value of evaluation regarding saltiness intensity in a sample that imitates ordinary food and a sample with 30% less salt. Tested using chopsticks equipped with Electirc Salt technology (current 0.1~0.5 mA). Thirty-one men and women aged 40-65 years who are/were currently or have been reducing salt in the past were asked about the saltiness intensity they perceived when eating the test food, and 29 of the 31 respondents answered that the saltiness had increased. |
The issue of "excessive salt intake" among Japanese people and dissatisfaction with the taste of low-sodium food
The daily salt intake of Japanese people aged 20 and over is 10.1g*4, which is much higher than the World Health Organization's (WHO) recommended salt intake of 5.0g*5. In addition, salt intake has not reached the "Healthy Japan 21 (2nd stage)*6 target for all age groups over 20 years old among both men and women*7. Target will be further lowered in the 3rd stage, making "excessive salt intake" the most important nutritional issue for Japanese people according to the Ministry of Health, Labor and Welfare.
In our questionnaire survey of persons who are currently eating a low-sodium diet or intend to do so*8, approximately 60% of the respondents felt issues exist in relation to low-sodium foods, and of those people, approximately 80% were dissatisfied with the taste. If low-sodium diets can be continued in better tasting way, it may lead to improvement in nutritional issues.
| 4. | Ministry of Health, Labour and Welfare National Health and Nutrition Survey 2019 |
| 5. | WHO Guidelines 2012 |
| 6. | Ministry of Health, Labour and Welfare Food Environment Strategy Initiative https://sustainable-nutrition.mhlw.go.jp/contents/sodium |
| 7. |
Ministry of Health, Labour and Welfare Basic Policy for the Comprehensive Promotion of the Health of the People
|
| 8. | Target: Men and women aged 40-79 living in the Tokyo metropolitan area (N=4,411) Format: Web survey Approximately 47% of all respondents are eating a low-sodium diet or intend to do so. |
"Electric Salt Spoon" addresses social issues and consumer needs
"Electric Salt Spoon" is a tableware-type device developed based on the concept of "a life with delicious food for all people to address social issues and consumer needs for low-sodium food taste.
In our survey*9, respondents who are trying to reduce salt consumption ranked ramen noodles in first place and miso soup in second place as the "foods they would like to eat with a strong taste instead of a thin taste. This indicates that there is a need to eat ramen with a strong taste as a "reward" for refraining from eating it due to their efforts to reduce salt intake, as well as a need to enjoy foods that are eaten on a daily basis, such as "soup," in a delicious way.
Directed at commercialization of Electric Salt, we have continued to develop tableware such as chopsticks and bowls, but we decided to first develop and market a "spoon" in consideration of the technical characteristics and the meals for which there are high consumer needs.
| 9. | Kirin Survey Period: January 2022 Target: 120 men and women aged 30~69 who are trying to reduce salt intake Format: CLT survey, multiple responses allowed. Press release regarding the results of this research (Monday, April 11, 2022) https://www.kirinholdings.com/jp/newsroom/release/2022/0411_01.html |
Product Overview, Sales Method and Developer's Comments |
||
| Product | ||
Product name |
Electric Salt Spoon |
|
Dimensions |
Approx. W250 x D38 x H25 (mm) |
|
Weight |
Approx. 60g (excluding batteries) |
|
Power Supply |
3V lithium battery (CR2) |
|
Price |
19,800 yen (tax included) |
|
Features |
A weak electric current is passed from the tip of the spoon to the food to enhance the taste of the meal*, including salty and umami taste. We have improved the technology so that the spoon can be used naturally at the dining table and designed the device with a focus on ease of use and durability. * There are individual differences in experience. Also, the feeling may vary depending on the dish. |
|
How to use |
Turn the power on with the switch on the handle of the spoon, select the desired intensity (4 levels), and use the spoon as you would a regular spoon. |
|
Details |
https://electricsalt.shop.kirin.co.jp/electricsalt-spoon/product/ES-S001/ * There are certain conditions under which this product may not be used (e.g. minors and persons fitted with a pacemaker or other medical electrical device). Please check the "Safety Precautions" on the official online store or on the product box. |
|
Recommendation |
It can be used with soups with lots of ingredients, curry, fried rice, food in a bowl, ramen noodles, and other meals in general. |
|
| Sales Method | ||
1. Official Online Store (https://electricsalt.shop.kirin.co.jp/) |
||
Initial sales volume |
200 units (planned) * Please apply from the product purchase page on the official online store. * If the number of applications exceeds the number of units to be sold, sales will be conducted by lottery. |
|
Application Period |
Monday, May 20, 2024 - Sunday, June 2, 2024 * In case of lottery sales, all applicants will be notified on Thursday, June 6. |
|
Shipping Schedule |
Mid-June 2024 * Sales are scheduled to continue after June. We will announce it on the official Electric Salt online store in due course. |
|
2. Hands Inc |
||
Start of sales |
June 2024 (Planned)
|
|
| Developer's Comments | ||
| Ai SATO Health Science Business Division, New Business Group | ||
| People trying to reduce salt intake often stated, "I understand the importance of reducing salt intake, but it is too hard for me to continue." This prompted us to start research and development of Electric Salt in 2019, which finally led to the marketing of the product after more than 5 years.
I hope people who have difficulty starting or continuing salt reduction will use Electric Salt as a tool to enjoy a wide range of meals and enrich their dietary life. |
||
Future development of "Electric Salt"
Kirin will continue to propose the development of tableware other than spoons and low-sodium food menus, and we will work with companies and local governments to expand the use of Electric Salt and its market. Electric Salt aims to provide services that enable consumers to enjoy eating healthy, delicious, and enjoyable foods and to realize a healthy and happy society.
About Kirin Holdings
(Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.
*: Creating Shared Value. Combined added value for consumers as well as for society at large.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240519949395/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
